Research Article
Effects of Long-Term Statin Therapy in Coronary Artery Disease Patients with or without Chronic Kidney Disease
Table 5
Adjusted determinants of MACE.
| | | Hazard ratio | 95% CI | value |
| | Group | | | | | CKD versus CAD + CKD | 0.42 | (0.31, 0.57) | <0.001 | | CKD versus CAD | 0.16 | (0.07, 0.38) | <0.001 | | Age (years) | 1.01 | (1.0, 1.03) | 0.065 | | Male (versus female) | 1.23 | (0.91, 1.68) | 0.183 | | Hypertension | 1.29 | (0.99, 1.68) | 0.061 | | Smoking | 1.58 | (1.19, 2.08) | 0.002 | | Myocardial infarction | 1.04 | (0.80, 1.34) | 0.791 | | β-blocker | 1.13 | (0.83, 1.53) | 0.449 | | Aspirin | 1.19 | (0.72, 1.98) | 0.505 | | Clinical parameters at baseline | | | | | LDL-C (mmol/l) | 1.001 | (1.0, 1.002) | 0.008 | | SBP (mmHg) | 0.99 | (0.98, 0.994) | <0.001 | | DBP (mmHg) | 1 | (0.99, 1.01) | 0.88 | | Clinical parameters at final observation | | | | | Total cholesterol (mmol/l) | 1.38 | (1.13, 1.68) | 0.002 | | LDL-C (mmol/l) | 0.89 | (0.70, 1.13) | 0.334 | | SBP (mmHg) | 1.01 | (1.001, 1.013) | 0.023 | | Glucose (mmol/l) | 1.06 | (1.01, 1.12) | 0.03 | | Statins | 0.25 | (0.2, 0.38) | <0.001 |
|
|
CAD, coronary artery disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular event; SBP, systolic blood pressure.
|
